STOCKHOLM, July 23, 2021 /PRNewswire/ -- Second
quarter
- Revenue amounted to €348.9m (€198.8m), an increase of 75.5%
with an organic growth of 79.0%.
- Operating profit (EBIT) was €46.2m (€-2.3m), representing an
operating margin of 13.3% (-1.2%).
- Net profit amounted to €33.5m (€-8.5m), which represents a net
profit margin of 9.6% (-4.3%).
- EBITDA was €71.8m (€25.3m), an increase by 183.9%. EBITDA
margin was 20.6% (12.7%).
- EBITDAaL amounted to €58.2m (€12.4m), corresponding to an
EBITDAaL margin of 16.7% (6.3%).
- Net cash flow from operating activities was €38.1m
(€38.3m).
- Basic/diluted earnings per share were
€0.203 (€-0.056).
- Covid-19-pandemic had a net positive impact on operating
performance.
First half
- Revenue amounted to €666.1m (€437.6m), an increase of 52.2%
with an organic growth of 56.4%.
- Operating profit (EBIT) was €87.8m (€4.1m), representing an
operating margin of 13.2% (0.9%).
- Net profit amounted to €59.8m (€-11.0m), which represents a net
profit margin of 9.0% (-2.5%).
- EBITDA was €137.3m (€54.3m), an increase by 152.7%. EBITDA
margin was 20.6% (12.4%).
- EBITDAaL amounted to €111.1m (€29.2m), corresponding to an
EBITDAaL margin of 16.7% (6.7%).
- Net cash flow from operating activities was €95.8m
(€74.9m).
- Basic/diluted earnings per share were
€0.377 (€-0.062).
REVENUE AND EARNINGS
|
€ millions (€m)
|
Q2 2021
|
Q2 2020
|
Growth
|
6M 2021
|
6M 2020
|
Growth
|
FY 2020
|
|
Revenue
|
348.9
|
198.8
|
76%
|
666.1
|
437.6
|
52%
|
997.8
|
|
Operating profit
(EBIT)
|
46.2
|
-2.3
|
2,114%
|
87.8
|
4.1
|
2,043%
|
61.3
|
|
Operating profit
margin
|
13.3%
|
-1.2%
|
|
13.2%
|
0.9%
|
|
6.1%
|
|
Net profit
|
33.5
|
-8.5
|
491%
|
59.8
|
-11.0
|
640%
|
27.3
|
|
Net profit
margin
|
9.6%
|
-4.3%
|
|
9.0%
|
-2.5%
|
|
2.7%
|
|
Basic/diluted
earnings/(loss) per share, €
|
0.203
|
-0.056
|
463%
|
0.377
|
-0.062
|
708%
|
0.182
|
|
|
|
|
|
|
|
|
|
EBITDA
|
71.8
|
25.3
|
184%
|
137.3
|
54.3
|
153%
|
157.5
|
|
EBITDA
margin
|
20.6%
|
12.7%
|
|
20.6%
|
12.4%
|
|
15.8%
|
|
EBITDAaL
|
58.2
|
12.4
|
368%
|
111.1
|
29.2
|
280%
|
108.5
|
|
EBITDAaL
margin
|
16.7%
|
6.3%
|
|
16.7%
|
6.7%
|
|
10.9%
|
|
EBITA
|
48.6
|
5.2
|
838%
|
92.7
|
14.1
|
559%
|
76.9
|
|
EBITA
margin
|
13.9%
|
2.6%
|
|
13.9%
|
3.2%
|
|
7.7%
|
Definition and reconciliation of alternative performance
measures are available at
www.medicover.com/financial-information
This interim report has not been subject to review by the
Company's auditor.
This is information that Medicover AB is obliged to make public
pursuant to the EU Market Abuse Regulation and the Securities
Markets Act. The information was submitted for publication through
the agency of the contact person set out below at 7.45 (CEST) on
23 July 2021. This interim report and
other information about Medicover is available at
medicover.com.
For further information, please contact:
Hanna Bjellquist, Head of
Investor Relations
Phone: +46 70 303 32 72
E-mail: hanna.bjellquist@medicover.com
Conference call: A conference call for analysts and
investors will be held today at 09.30 CEST. To listen in please
register here. To ask questions please dial in and use code:
2561816SE: 08-566 184 67
DE: +49 (0) 305 200 2085
UK: +44 (0) 2071 928 338
US: +1 646 741 3167
Medicover is a leading international healthcare and
diagnostic services company and was founded in 1995. Medicover
operates a large number of ambulatory clinics, hospitals,
specialty-care facilities,laboratories and blood-drawing
points and the largest markets are Poland and Germany. In 2020, Medicover had revenue of
EUR 998 million and more than 32,000
employees. For more information, go to www.medicover.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medicover/r/interim-report-april-june-2021,c3388529
The following files are available for download:
|
https://mb.cision.com/Main/15662/3388529/1447679.pdf
|
Interim report Q2
2021
|